(Q37705457)
Statements
Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden (English)
Khalid Abubaker
Orla McNally
Jock K Findlay